| Patient | Joe Frazier |
|---|---|
| Date of birth | 1962-01-12 |
| Identifiers | MRN HR-BX004-SYN; SSN (made up) 000-04-5590 |
| Document date | 2026-02-16 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1964 | Broken left thumb in the 1964 Olympic final | D (CLM-0003) |
| 1964 | Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975) | D (CLM-0004) |
| 1965 to 1976, and one bout in 1981 | Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer see | D (CLM-0005, CLM-0006) |
| early 2000s | Diabetes and high blood pressure, reported publicly | D (CLM-0008) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2026-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2026-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-16 | active | S |
Positive for the concerns in the history of present illness. Alert, direct and good-humored; oriented; fluent conversation with good recall of recent events; PHQ-9 score 4. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent in all activities; walks without an aid; reads with his right eye. [S]
Vital signs recorded on 2026-02-16; see the Vital Signs section. Mental status: Alert, direct and good-humored; oriented; fluent conversation with good recall of recent events; PHQ-9 score 4. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-16 | Body height | 182 | cm | S |
| 2026-02-16 | Body weight | 104 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 31.4 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 152 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 76 | /min | S |
| 2026-02-16 | Respiratory rate | 16 | /min | S |
| 2026-02-16 | Body temperature | 36.7 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.4 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2026-02-16 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 2026-02-16 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-16 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 77 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2026-02-16 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-02-16 | Cholesterol [Mass/volume] in Serum or Plasma | 212 | mg/dL | <=199 mg/dL | High | S |
| 2026-02-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | Goal below 70 mg/dL with diabetes and other risk factors | High | S |
| 2026-02-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 2026-02-16 | Triglyceride [Mass/volume] in Serum or Plasma | 210 | mg/dL | <=149 mg/dL | High | S |
| 2026-02-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 10-40 U/L | High | S |
| 2026-02-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 42 | U/L | 7-55 U/L | Normal | S |
| 2026-02-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2026-02-16 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-16 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-16 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-16 | Platelets [#/volume] in Blood by Automated count | 138 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-02-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-02-16 | Total score [AUDIT-C] | 2 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | active | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |